Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

This article has no abstract
Epistemonikos ID: 6c19f0c89e27c7f2cf1dc25ca16d16ed08f5ca0a
First added on: Feb 16, 2025